

Simone Lista

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/863454/simone-lista-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

138
papers

4,987
citations

36
h-index

67
g-index

153
ext. papers

6,562
ext. citations

5
avg, IF

5.58
L-index

#	Paper	IF	Citations
138	Exercise and the hallmarks of peripheral arterial disease.. <i>Atherosclerosis</i> , 2022 , 350, 41-50	3.1	0
137	Defining and assessing intrinsic capacity in older people: a systematic review and a proposed scoring system.. <i>Ageing Research Reviews</i> , 2022 , 101640	12	1
136	Partial Volume Correction Increases the Sensitivity of 18F-Florbetapir-Positron Emission Tomography for the Detection of Early Stage Amyloidosis.. <i>Frontiers in Aging Neuroscience</i> , 2021 , 13, 748198	5.3	1
135	Physical Exercise and Alzheimer's Disease: Effects on Pathophysiological Molecular Pathways of the Disease. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	8
134	Future avenues for Alzheimer's disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery. <i>Neuropharmacology</i> , 2021 , 185, 108081	5.5	12
133	The β Secretase BACE1 in Alzheimer's Disease. <i>Biological Psychiatry</i> , 2021 , 89, 745-756	7.9	107
132	Aptamer prediction of brain amyloid- β status in cognitively normal individuals at risk for Alzheimer's disease. <i>PLoS ONE</i> , 2021 , 16, e0243902	3.7	1
131	MiRNA-15b and miRNA-125b are associated with regional A β PET and FDG-PET uptake in cognitively normal individuals with subjective memory complaints. <i>Translational Psychiatry</i> , 2021 , 11, 78	8.6	6
130	Plasma β Secretase1 concentrations correlate with basal forebrain atrophy and neurodegeneration in cognitively healthy individuals at risk for AD. <i>Alzheimer's and Dementia</i> , 2021 , 17, 629-640	1.2	4
129	Omics sciences for systems biology in Alzheimer's disease: State-of-the-art of the evidence. <i>Ageing Research Reviews</i> , 2021 , 69, 101346	12	17
128	Exercise interventions in Alzheimer's disease: A systematic review and meta-analysis of randomized controlled trials. <i>Ageing Research Reviews</i> , 2021 , 72, 101479	12	5
127	Association of plasma A β 40/A β 42 ratio and brain A β accumulation: testing a whole-brain PLS-VIP approach in individuals at risk of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2021 , 107, 57-69	5.6	1
126	Association of plasma YKL-40 with brain amyloidosis, memory performance, and sex in subjective memory complainers. <i>Alzheimer's and Dementia</i> , 2020 , 16, e041753	1.2	
125	Aging and sex impact plasma NFL and t-Tau trajectories in individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020 , 16, e041792	1.2	
124	Sensitivity and specificity of EEG biomarkers of AD at the preclinical stage. <i>Alzheimer's and Dementia</i> , 2020 , 16, e045832	1.2	
123	Cortical microstructural changes and amyloid beta burden in cognitively normal subjective memory complainers. <i>Alzheimer's and Dementia</i> , 2020 , 16, e046014	1.2	
122	Sex differences in cortical microstructural changes in asymptomatic individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020 , 16, e046105	1.2	

121	Coronavirus Lockdown: Forced Inactivity for the Oldest Old?. <i>Journal of the American Medical Directors Association</i> , 2020 , 21, 988-989	5.9	18
120	The meta-memory ratio: a new cohort-independent way to measure cognitive awareness in asymptomatic individuals at risk for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 57	9	7
119	Exercise benefits on Alzheimer's disease: State-of-the-science. <i>Ageing Research Reviews</i> , 2020 , 62, 101108	5.3	53
118	In vivo staging of regional amyloid deposition predicts functional conversion in the preclinical and prodromal phases of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020 , 93, 98-108	5.6	10
117	The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases. <i>Expert Review of Molecular Diagnostics</i> , 2020 , 20, 421-441	3.8	19
116	Successful aging: insights from proteome analyses of healthy centenarians. <i>Aging</i> , 2020 , 12, 3502-3515	5.6	18
115	Association of brain network dynamics with plasma biomarkers in subjective memory complainers. <i>Neurobiology of Aging</i> , 2020 , 88, 83-90	5.6	3
114	Plasma tau correlates with basal forebrain atrophy rates in people at risk for Alzheimer disease. <i>Neurology</i> , 2020 , 94, e30-e41	6.5	13
113	Secretase1 biological markers for Alzheimer's disease: state-of-art of validation and qualification. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 130	9	2
112	Awareness of cognitive decline trajectories in asymptomatic individuals at risk for AD. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 129	9	8
111	Association of plasma YKL-40 with brain amyloid- β levels, memory performance, and sex in subjective memory complainers. <i>Neurobiology of Aging</i> , 2020 , 96, 22-32	5.6	4
110	Resting-state posterior alpha rhythms are abnormal in subjective memory complaint seniors with preclinical Alzheimer's neuropathology and high education level: the INSIGHT-preAD study. <i>Neurobiology of Aging</i> , 2020 , 90, 43-59	5.6	12
109	microRNA-Based Biomarkers in Alzheimer's Disease (AD). <i>Frontiers in Neuroscience</i> , 2020 , 14, 585432	5.1	28
108	Age and sex impact plasma NFL and t-Tau trajectories in individuals with subjective memory complaints: a 3-year follow-up study. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 147	9	8
107	Different Clinical Contexts of Use of Blood Neurofilament Light Chain Protein in the Spectrum of Neurodegenerative Diseases. <i>Molecular Neurobiology</i> , 2020 , 57, 4667-4691	6.2	14
106	Biomarkers for Alzheimer's Disease (AD) and the Application of Precision Medicine. <i>Journal of Personalized Medicine</i> , 2020 , 10,	3.6	5
105	A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease. <i>Frontiers in Immunology</i> , 2020 , 11, 456	8.4	87
104	Biomarker-guided clustering of Alzheimer's disease clinical syndromes. <i>Neurobiology of Aging</i> , 2019 , 83, 42-53	5.6	23

103	EEG evidence of compensatory mechanisms in preclinical Alzheimer's disease. <i>Brain</i> , 2019 , 142, 2096-2112.	11.2	47
102	Lithium as a Treatment for Alzheimer's Disease: The Systems Pharmacology Perspective. <i>Journal of Alzheimer's Disease</i> , 2019 , 69, 615-629	4.3	28
101	Blood-based diagnostics of Alzheimer's disease. <i>Expert Review of Molecular Diagnostics</i> , 2019 , 19, 613-623	3.8	8
100	The neuroinflammatory biomarker YKL-40 for neurodegenerative diseases: advances in development. <i>Expert Review of Proteomics</i> , 2019 , 16, 593-600	4.2	20
99	Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019 , 15, 764-775	1.2	86
98	Differential default mode network trajectories in asymptomatic individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019 , 15, 940-950	1.2	31
97	Commentary: Development of the Blood-Based Alzheimer's Disease Liquid Biopsy. <i>Journal of Prevention of Alzheimer's Disease</i> , 2019 , 6, 182-184	3.8	1
96	Biomarker-Drug and Liquid Biopsy Co-development for Disease Staging and Targeted Therapy: Cornerstones for Alzheimer's Precision Medicine and Pharmacology. <i>Frontiers in Pharmacology</i> , 2019 , 10, 310	5.6	23
95	The Alzheimer Precision Medicine Initiative. <i>Journal of Alzheimer's Disease</i> , 2019 , 68, 1-24	4.3	48
94	Time for the systems-level integration of aging: Resilience enhancing strategies to prevent Alzheimer's disease. <i>Progress in Neurobiology</i> , 2019 , 181, 101662	10.9	26
93	Brain A β load association and sexual dimorphism of plasma BACE1 concentrations in cognitively normal individuals at risk for AD. <i>Alzheimer's and Dementia</i> , 2019 , 15, 1274-1285	1.2	9
92	Latent class analysis identifies functional decline with Amsterdam IADL in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019 , 5, 553-562	6	5
91	Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease?. <i>Dialogues in Clinical Neuroscience</i> , 2019 , 21, 177-191	5.7	13
90	Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia. <i>Alzheimer's and Dementia</i> , 2019 , 15, 465-476	1.2	127
89	Relationship between Basal Forebrain Resting-State Functional Connectivity and Brain Amyloid- β Deposition in Cognitively Intact Older Adults with Subjective Memory Complaints. <i>Radiology</i> , 2019 , 290, 167-176	20.5	15
88	Cognitive and neuroimaging features and brain β amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study. <i>Lancet Neurology</i> , 2018 , 17, 335-346	24.1	113
87	Precision pharmacology for Alzheimer's disease. <i>Pharmacological Research</i> , 2018 , 130, 331-365	10.2	60
86	Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: A β total-tau, phosphorylated-tau, NFL, neurogranin, and YKL-40. <i>Alzheimer's and Dementia</i> , 2018 , 14, 492-501	1.2	71

85	Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology. <i>Journal of Alzheimer's Disease</i> , 2018 , 64, S47-S105	4.3	84
84	Increased Plasma Beta-Secretase 1 May Predict Conversion to Alzheimer's Disease Dementia in Individuals With Mild Cognitive Impairment. <i>Biological Psychiatry</i> , 2018 , 83, 447-455	7.9	62
83	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. <i>World Journal of Biological Psychiatry</i> , 2018 , 19, 244-328	3.8	148
82	Association of cerebrospinal fluid Synuclein with total and phospho-tau protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer's disease biomarkers. <i>Alzheimer's and Dementia</i> , 2018 , 14, 1623-1631	1.2	30
81	Sex differences in functional and molecular neuroimaging biomarkers of Alzheimer's disease in cognitively normal older adults with subjective memory complaints. <i>Alzheimer's and Dementia</i> , 2018 , 14, 1204-1215	1.2	40
80	Gray Matter Network Disruptions and Regional Amyloid Beta in Cognitively Normal Adults. <i>Frontiers in Aging Neuroscience</i> , 2018 , 10, 67	5.3	18
79	Aptamers as biomarkers for neurological disorders. Proof of concept in transgenic mice. <i>PLoS ONE</i> , 2018 , 13, e0190212	3.7	6
78	Precision medicine and drug development in Alzheimer's disease: the importance of sexual dimorphism and patient stratification. <i>Frontiers in Neuroendocrinology</i> , 2018 , 50, 31-51	8.9	29
77	Systems Biology Methods for Alzheimer's Disease Research Toward Molecular Signatures, Subtypes, and Stages and Precision Medicine: Application in Cohort Studies and Trials. <i>Methods in Molecular Biology</i> , 2018 , 1750, 31-66	1.4	23
76	Blood-Based Biomarker Screening with Agnostic Biological Definitions for an Accurate Diagnosis Within the Dimensional Spectrum of Neurodegenerative Diseases. <i>Methods in Molecular Biology</i> , 2018 , 1750, 139-155	1.4	10
75	Evaluation of amyloid status in a cohort of elderly individuals with memory complaints: validation of the method of quantification and determination of positivity thresholds. <i>Annals of Nuclear Medicine</i> , 2018 , 32, 75-86	2.5	33
74	P3-218: NOVEL ALZHEIMER'S DISEASE BIOMARKER-GUIDED DIAGNOSTIC WORKFLOW USING THE ADDED VALUE OF SIX COMBINED CEREBROSPINAL FLUID CANDIDATES: Aβ-42, TOTAL-TAU, PHOSPHORYLATED-TAU, NFL, NEUROGRANIN, AND YKL-40 2018 , 14, P1154-P1155		1
73	P4-072: INCREASED PLASMA BACE1 CONCENTRATIONS IN WOMEN WITH SUBJECTIVE MEMORY COMPLAINTS: CORRELATION WITH PLASMA NFL 2018 , 14, P1461-P1462		
72	P2-237: ASSOCIATION OF CSF ALPHA-SYNUCLEIN AND TAU CONCENTRATIONS WITH AMYLOID MEAN CORTICAL STANDARD UPTAKE VALUE RATIOS IN PRECLINICAL SUBJECTIVE MEMORY COMPLAINERS STRATIFIED BY ALZHEIMER'S DISEASE BIOMARKERS 2018 , 14, P762-P762		
71	O4-07-04: INCREASED RESILIENCE TO ALZHEIMER'S DISEASE PATHOPHYSIOLOGY IN MEN WITH SUBJECTIVE MEMORY COMPLAINTS COMPARED TO WOMEN 2018 , 14, P1419-P1420		
70	O3-09-02: CORRELATION AND LONGITUDINAL DYNAMICS OF PLASMA NFL AND TAU CONCENTRATIONS IN AMYLOID-PET NEGATIVE INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS 2018 , 14, P1036-P1037		
69	P4-186: INNOVATIVE BIOMARKER-GUIDED DIAGNOSTIC SYSTEM FROM PRECLINICAL TO ALZHEIMER'S DISEASE DEMENTIA 2018 , 14, P1510-P1511		
68	P2-397: REDUCED BASAL FOREBRAIN FUNCTIONAL CONNECTIVITY IN WOMEN WITH SUBJECTIVE MEMORY COMPLAINTS COMPARED TO MEN 2018 , 14, P855-P856		

67	P2-246: INCREASED LONGITUDINAL DYNAMICS OF PLASMA YKL-40 CONCENTRATIONS IN AMYLOID-PET POSITIVE INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS 2018 , 14, P767-P768		
66	P2-249: CORRELATIONS AND ALTERED LONGITUDINAL DYNAMICS OF PLASMA BACE1 AND NFL CONCENTRATIONS IN INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS 2018 , 14, P768-P769		
65	O3-12-04: THE NEURONAL COMPENSATION MODEL OF THE PRECLINICAL STAGE OF ALZHEIMER'S DISEASE: RESULTS FROM THE INSIGHT-PRE AD STUDY 2018 , 14, P1051-P1053		
64	Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. <i>Nature Reviews Neurology</i> , 2018 , 14, 639-652	15	257
63	P2-355: CORRELATION OF FUNCTIONAL MRI CONNECTOMES WITH PATHOPHYSIOLOGICAL ALZHEIMER'S PLASMA BIOMARKERS AND RISK FACTORS IN SUBJECTIVE MEMORY COMPLAINERS 2018 , 14, P824-P825		
62	P1-431: APOE-DEPENDENT LONGITUDINAL CHANGES IN DEFAULT MODE NETWORK FUNCTIONAL CONNECTIVITY IN SUBJECTIVE MEMORY COMPLAINERS 2018 , 14, P474-P474		1
61	Basal Forebrain Volume, but Not Hippocampal Volume, Is a Predictor of Global Cognitive Decline in Patients With Alzheimer's Disease Treated With Cholinesterase Inhibitors. <i>Frontiers in Neurology</i> , 2018 , 9, 642	4.1	18
60	Effect of Alzheimer's disease risk and protective factors on cognitive trajectories in subjective memory complainers: An INSIGHT-preAD study. <i>Alzheimer's and Dementia</i> , 2018 , 14, 1126-1136	1.2	12
59	Synaptic degeneration and neurogranin in the pathophysiology of Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2017 , 17, 47-57	4.3	44
58	Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer's disease and other neurodegenerative diseases. <i>Expert Review of Proteomics</i> , 2017 , 14, 285-299	4.2	49
57	Preclinical Alzheimer's disease: A systematic review of the cohorts underlying the concept. <i>Alzheimer's and Dementia</i> , 2017 , 13, 454-467	1.2	49
56	Two-level diagnostic classification using cerebrospinal fluid YKL-40 in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017 , 13, 993-1003	1.2	35
55	A Precision Medicine Initiative for Alzheimer's disease: the road ahead to biomarker-guided integrative disease modeling. <i>Climacteric</i> , 2017 , 20, 107-118	3.1	84
54	Evolving Relevance of Neuroproteomics in Alzheimer's Disease. <i>Methods in Molecular Biology</i> , 2017 , 1598, 101-115	1.4	11
53	Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer's disease. <i>Neurochemistry International</i> , 2017 , 108, 355-360	4.4	38
52	Disrupted white matter structural networks in healthy older adult APOE ϵ carriers - An international multicenter DTI study. <i>Neuroscience</i> , 2017 , 357, 119-133	3.9	23
51	Cerebrospinal Fluid Neurogranin as a Biomarker of Neurodegenerative Diseases: A Cross-Sectional Study. <i>Journal of Alzheimer's Disease</i> , 2017 , 59, 1327-1334	4.3	28
50	Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer's disease. <i>Scientific Reports</i> , 2017 , 7, 11706	4.9	53

49	Revolution of Resting-State Functional Neuroimaging Genetics in Alzheimer's Disease. <i>Trends in Neurosciences</i> , 2017 , 40, 469-480	13.3	25
48	Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. <i>Alzheimer's and Dementia</i> , 2017 , 13, 45-58 ^{1.2}		163
47	A common challenge in older adults: Classification, overlap, and therapy of depression and dementia. <i>Alzheimer's and Dementia</i> , 2017 , 13, 59-71	1.2	70
46	Cerebrospinal Fluid Stanniocalcin-1 as a Biomarker for Alzheimer's Disease and Other Neurodegenerative Disorders. <i>NeuroMolecular Medicine</i> , 2017 , 19, 154-160	4.6	10
45	[P2B79]: ACCURACY OF MRI CLASSIFICATION ALGORITHMS IN A TERTIARY MEMORY CENTER CLINICAL ROUTINE COHORT 2017 , 13, P772-P774		1
44	Alzheimer's Disease Diagnosis Relies on a Twofold Clinical-Biological Algorithm: Three Memory Clinic Case Reports. <i>Journal of Alzheimer's Disease</i> , 2017 , 60, 577-583	4.3	1
43	Fully Automatic MRI-Based Hippocampus Volumetry Using FSL-FIRST: Intra-Scanner Test-Retest Stability, Inter-Field Strength Variability, and Performance as Enrichment Biomarker for Clinical Trials Using Prodromal Target Populations at Risk for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017 , 60, 151-164	4.3	4
42	Cortical amyloid accumulation is associated with alterations of structural integrity in older people with subjective memory complaints. <i>Neurobiology of Aging</i> , 2017 , 57, 143-152	5.6	13
41	Application of Systems Theory in Longitudinal Studies on the Origin and Progression of Alzheimer's Disease. <i>Methods in Molecular Biology</i> , 2016 , 1303, 49-67	1.4	29
40	Dementia: The rising global tide of cognitive impairment. <i>Nature Reviews Neurology</i> , 2016 , 12, 131-2	15	18
39	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. <i>Alzheimer's and Dementia</i> , 2016 , 12, 292-323	1.2	832
38	The phenotypical core of Alzheimer's disease-related and nonrelated variants of the corticobasal syndrome: A systematic clinical, neuropsychological, imaging, and biomarker study. <i>Alzheimer's and Dementia</i> , 2016 , 12, 786-95	1.2	21
37	Effects of rivastigmine on visual attention in subjects with amnesic mild cognitive impairment: A serial functional MRI activation pilot-study. <i>Psychiatry Research - Neuroimaging</i> , 2016 , 249, 84-90	2.9	7
36	Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease. <i>Neuropharmacology</i> , 2016 , 108, 128-35	5.5	12
35	Reduced Regional Cortical Thickness Rate of Change in Donepezil-Treated Subjects With Suspected Prodromal Alzheimer's Disease. <i>Journal of Clinical Psychiatry</i> , 2016 , 77, e1631-e1638	4.6	25
34	Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016 , 3, 27-34	5.2	35
33	Biomarker-guided classification scheme of neurodegenerative diseases. <i>Journal of Sport and Health Science</i> , 2016 , 5, 383-387	8.2	19
32	DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences--part 1: general aspects and paradigmatic discussion of depressive disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015 , 265, 5-18	5.1	19

31	CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study. <i>Alzheimer's and Dementia</i> , 2015 , 11, 1306-15	1.2	87
30	Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future. <i>Expert Review of Neurotherapeutics</i> , 2015 , 15, 83-105	4.3	53
29	DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences Part 2: bipolar disorders, schizophrenia spectrum disorders, anxiety disorders, obsessive-compulsive disorders, trauma- and stressor-related disorders, personality disorders, substance-related and addictive disorders, neurocognitive disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015 , 265, 103-112	5.1	19
28	Paths to Alzheimer's disease prevention: from modifiable risk factors to biomarker enrichment strategies. <i>Journal of Nutrition, Health and Aging</i> , 2015 , 19, 154-63	5.2	34
27	Prediction of Alzheimer's Disease Dementia: Data from the GuidAge Prevention Trial. <i>Journal of Alzheimer's Disease</i> , 2015 , 48, 793-804	4.3	20
26	Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2015 , 48 Suppl 1, S171-91	4.3	29
25	Biomarkers in Sporadic and Familial Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015 , 47, 291-317	4.3	61
24	Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research. <i>Alzheimer's and Dementia</i> , 2015 , 11, 549-60	1.2	159
23	Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015 , 11, 1041-9	1.2	78
22	Cerebrospinal fluid analysis in Alzheimer's disease: technical issues and future developments. <i>Journal of Neurology</i> , 2014 , 261, 1234-43	5.5	29
21	CSF A β -42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014 , 10, 381-92	1.2	53
20	Schizophrenia: Blood-Serum-Plasma Metabolomics. <i>Advances in Biological Psychiatry</i> , 2014 , 27-27		
19	Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020. <i>Biochemical Pharmacology</i> , 2014 , 88, 426-49	6	84
18	P2-192: ADVANCED DIFFUSION WEIGHTING IMAGING (DWI) TRACTOGRAPHY OF THE LIMBIC SYSTEM: NOVEL BIOMARKERS OF NEURODEGENERATIVE CHANGES DURING PROGRESSION/CONVERSION FROM COGNITIVE NORMALITY TO AD DEMENTIA 2014 , 10, P541-P542		1
17	IC-P-067: ADVANCED DIFFUSION WEIGHTING IMAGING (DWI) TRACTOGRAPHY OF THE LIMBIC SYSTEM: NOVEL BIOMARKERS OF NEURODEGENERATIVE CHANGES DURING PROGRESSION/CONVERSION FROM COGNITIVE NORMALITY TO AD DEMENTIA 2014 , 10, P37-P37		
16	Increased plasma TACE activity in subjects with mild cognitive impairment and patients with Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2014 , 41, 877-86	4.3	21
15	Blood and plasma-based proteomic biomarker research in Alzheimer's disease. <i>Progress in Neurobiology</i> , 2013 , 101-102, 1-17	10.9	88
14	Use of biomarkers and imaging to assess pathophysiology, mechanisms of action and target engagement. <i>Journal of Nutrition, Health and Aging</i> , 2013 , 17, 54-63	5.2	24

13	Have we learnt all we need to know from genetic studies - is genetics over in Alzheimer's disease?. <i>Alzheimer's Research and Therapy</i> , 2013 , 5, 11	9	4
12	Biological and methodical challenges of blood-based proteomics in the field of neurological research. <i>Progress in Neurobiology</i> , 2013 , 101-102, 18-34	10.9	38
11	Relevance of magnetic resonance imaging for early detection and diagnosis of Alzheimer disease. <i>Medical Clinics of North America</i> , 2013 , 97, 399-424	7	108
10	Imaging epigenetics in Alzheimer's disease. <i>Current Pharmaceutical Design</i> , 2013 , 19, 6393-415	3.3	31
9	Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot. <i>Alzheimer's and Dementia</i> , 2012 , 8, 312-36	1.2	92
8	Chromosome 9p21.3 genotype is associated with vascular dementia and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2011 , 32, 1231-5	5.6	49
7	Learning discloses abnormal structural and functional plasticity at hippocampal synapses in the APP23 mouse model of Alzheimer's disease. <i>Learning and Memory</i> , 2010 , 17, 236-40	2.8	24
6	Optimization protocol for amyloid- β peptides detection in human cerebrospinal fluid using SELDI TOF MS. <i>Proteomics - Clinical Applications</i> , 2010 , 4, 352-7	3.1	26
5	Potential therapeutic usefulness of hydrogen peroxide in conditions of brain ischemia. <i>Medical Hypotheses</i> , 2008 , 71, 162	3.8	
4	Analysis of mitochondrial DNA by PCR/DHPLC as a diagnostic tool to differentiate schistosomes species and strains. <i>Medical Hypotheses</i> , 2007 , 68, 707-8	3.8	
3	Potential therapeutical effects of topical halofuginone hydrobromide in keloid management. <i>Medical Hypotheses</i> , 2007 , 69, 707	3.8	1
2	Demineralized bone matrix enriched with human recombinant interleukin-11: a novel therapeutic option in treatment of delayed unions and nonunions?. <i>Medical Hypotheses</i> , 2007 , 69, 954	3.8	
1	An expanded microarray platform for diagnosis of nonbacterial sepsis: potential usefulness for immunosuppressed patients. <i>Medical Hypotheses</i> , 2006 , 67, 1001	3.8	